NCT01167751

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Royan Institute · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

One of the important reasons for human dying is Ischemic heart disease (IHD). The most reason is coronary artery disease. Beside morbidity, IHD induce myocardial infarction and necrosis which due to congestive heart failure. One therapeutic method is cellular cardiomyoplasty, which is to produce and substitute the cardiac cells with stem cell transplantation. Cell therapy is a potential therapeutic method to prevent ventricular remodeling after acute myocardial infarction. Human and animal studies have shown that stem cell trans plantation to myocardial infarcted zone can improve heart contractile function. The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation in patients with myocardial infarction.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
BIOLOGICAL	MNC	Implantation of BM derived MNC
BIOLOGICAL	AC 133	Implantation of BM derived AC133
BIOLOGICAL	Control	Injection of cell carrier

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-06-01
• Completion: 2012-07-01
• First posted: 2010-07-22
• Last updated: 2016-06-21

Locations

1 site across 1 country: Iran